From rapalogs to anti-aging formula

Area of Science:

• Gerontology and aging research.
• Pharmacology of aging.
• Cellular senescence and longevity.

Background:

• Mammalian target of rapamycin (mTOR) inhibitors, like rapamycin (Sirolimus) and Everolimus, are identified as gerosuppressants.
• Rapamycin has demonstrated life-extending properties across various species and can mitigate age-related conditions.
• These drugs show potential in rejuvenating stem cells, immune function, and metabolic health.

Purpose of the Study:

• To explore the potential of combining rapamycin with other pharmacologic agents for enhanced anti-aging effects.
• To propose a comprehensive anti-aging strategy integrating drug combinations, lifestyle interventions, and diet.
• To investigate methods for maximizing therapeutic benefits while minimizing adverse effects of anti-aging interventions.

Main Methods:

• Review of existing literature on mTOR inhibitors and other pharmacologic agents relevant to aging.
• Conceptual framework for drug combination therapy targeting aging pathways.
• Integration of lifestyle factors, including physical exercise and a specific anti-aging diet (Koschei formula).

Main Results:

• Rapalogs, such as rapamycin, are potent suppressors of cellular senescence and aging.
• Potential synergistic effects are hypothesized when rapamycin is combined with metformin, angiotensin II signaling inhibitors, statins, propranolol, aspirin, and PDE5 inhibitors.
• The proposed combination strategy aims to enhance anti-aging outcomes and reduce potential side effects.

Conclusions:

• Rapalogs represent a promising class of drugs for combating aging and age-related diseases.
• A multi-faceted approach combining pharmacotherapy, exercise, and diet offers a promising strategy for maximizing longevity and healthspan.
• Further research into these rational drug combinations and lifestyle interventions is warranted to validate their efficacy and safety.